GlassScriptPhysician profile
Keith Jones
NPI 1649634296
$13,948.11
in general payments reported to CMS, 2019-2025
23 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,413 · 2022: $2,061 · 2023: $3,420 · 2024: $3,374 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,469.50 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,465.39 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $2,279.18 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,540.84 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,292.72 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,240.90 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $1,171.12 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $1,001.43 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $974.07 | 2022-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $556.58 | 2022-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $315.99 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $148.42 | 2022-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $141.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $129.20 | 2021 | |
| Esperion Therapeutics, INC. | $124.94 | 2022 | |
| Noven Pharmaceuticals, INC. | $122.50 | 2024 | Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $113.89 | 2022-2024 | Aplenzin, Wellbutrin |
| Livanova USA, INC. | $112.47 | 2022 | |
| Supernus Pharmaceuticals, INC. | $64.27 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $50.51 | 2021-2022 | |
| Harmony Biosciences LLC | $43.74 | 2025 | |
| Acadia Pharmaceuticals INC | $24.66 | 2022 | |
| Alfasigma USA, INC. | $20.12 | 2021 | |
| Eisai INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.